Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...

UnitedHealth Group has had a tumultuous year, marred by poor performance and controversy. Eli Lilly has thrived as it's taken ...

Good news for people on GLP-1 therapy who hate needles: Trial data out this week shows that an experimental pill developed by ...

Lilly has a new pill, called orforglipron, it plans to launch next year. On Thursday, the company reported the results of a ...

Eli Lilly ( LLY 1.19%) and Novo Nordisk ( NVO 2.44%) are two of the leading companies in the fast-growing GLP-1 weight loss ...

Meanwhile, the 25-milligram dose of Novo Nordisk's oral semaglutide helped patients lose up to 16.6% of their weight on ...

Pop Mart, the Chinese firm behind the mischievously grinning, nine-toothed Labubu dolls that shoppers have queued up to buy ...

Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). In a decade, Eli Lilly could be in the ...

Discover why Eli Lilly's stock downturn may present new opportunities. Learn about valuation, Zepbound pricing, and 2026 ...

Lilly has now submitted a new drug application (NDA) for orforglipron to the FDA for use in adults with obesity.

The filing comes as Novo fights tooth-and-nail with rival Lilly to regain its footing at the top of the weight loss market.

Novo Nordisk trades 32% below fair value with a 3.6% yield, semaglutide at 74% of sales, EPS rebound post '26, and pipeline ...